Sobi North America’s Doptelet Approved by FDA for Pediatric ITP Treatment
Sobi North America, the North American affiliate of Swedish Orphan Biovitrum AB (Sobi), announced today...
Hengrui and GSK Enter Global Licensing Pact for PDE3/4 Inhibitor HRS-9821
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced on July 28, 2025, that it...
Pfizer and BioNTech’s LP.8.1 COVID-19 Vaccine Gets EMA CHMP Nod
US giant Pfizer Inc., (NYSE: PFE) and Germany-based BioNTech SE (NASDAQ: BNTX) announced today that...
Sansure Biotech’s Gene Polymorphism Detection Kits Receive NMPA Class III IVD Certification
China-based Sansure Biotech Inc. (SHA: 688289) announced on July 28, 2025, that it has received...
NMPA Approves Ambroxol Hydrochloride Oral Drops for Over-the-Counter Sale
China’s National Medical Products Administration (NMPA) has approved the switch of ambroxol hydrochloride oral drops...
Biogen’s Zurzuvae Receives Positive CHMP Opinion for Postpartum Depression Treatment
US-based Biogen (NASDAQ: BIIB) announced that the Committee for Medicinal Products for Human Use (CHMP)...
GSK’s Blenrep Approved in EU for Relapsed or Refractory Multiple Myeloma
UK-based GlaxoSmithKline (GSK; NYSE: GSK) announced today that Blenrep has received European Union (EU) approval...
Sanofi’s Sarclisa Approved in EU for Newly Diagnosed Multiple Myeloma
France-based Sanofi (NASDAQ: SNY) announced that the European Commission has approved its anti-CD38 monoclonal antibody...
Velavigo Closes $60 Million Pre-A+ Financing Round to Advance Global Clinical Trials
Velavigo, a Shanghai-based pharmaceutical startup, has reportedly secured USD 60 million in a Pre-A+ financing...
Matchpoint Therapeutics Partners with Novartis to Develop Oral Covalent Inhibitors for Inflammatory Diseases
Matchpoint Therapeutics, a privately held biotechnology company based in Watertown, Massachusetts, announced an exclusive option...
SinoCellTech’s SCT640C Injection Receives NMPA Approval for RA Clinical Trials
China-based SinoCellTech Group Ltd (SHA: 688520) announced today that its self-developed product, SCT640C injection, has...
Hengrui Pharmaceuticals’ HRS8179 and HRS-1893 Receive NMPA Clinical Trial Approval
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced today that it has received clinical...
Cryofocus Medtech’s Asthma Cryoablation System Granted FDA Breakthrough Device Designation
China-based Cryofocus Medtech (Shanghai) Co., Ltd. (HKG: 6922) announced today that its self-developed asthma cryoablation...
3Sbio and Pfizer Finalize Licensing Agreement for PD-1/VEGF Bispecific Antibody SSGJ-707
China-based 3Sbio Inc. (HKG: 1530) announced today that its global licensing agreement with Pfizer Inc.,...
Roche AG Reports 7% Sales Growth in H1 2025, Driven by Pharmaceuticals Expansion
Swiss giant Roche AG (SWX: ROG, OTCMKTS: RHHBY) announced its H1 2025 financial results, reporting...
GenFleet Therapeutics Announces Fast Track Designation for GFH375/VS-7375 in Pancreatic Cancer
China-based GenFleet Therapeutics announced on July 25, 2025, that its oral KRAS G12D inhibitor, GFH375/VS-7375,...
Leads Biolabs Lists on Hong Kong Stock Exchange in $189 Million IPO
China-based Leads Biolabs (HKG: 9887) officially listed on the Main Board of the Hong Kong...
Everest Medicines Completes HK$1.57 Billion Share Placement to Advance R&D and Commercialization
China-based Everest Medicines (HKG: 1952) announced today the completion of a share placement of 22,561,000...
Yangtze River Pharmaceutical’s Tadalafil Hydrochloride Tablets Approved for ED Treatment in China
China-based Yangtze River Pharmaceutical Group announced on July 25, 2025, that its Class 1 innovative...
Ipsen’s Cabometyx Approved by European Commission for Neuroendocrine Tumors
France-based pharmaceutical company Ipsen S.A. (EPA: IPN, OTCMKTS: IPSEY) announced that its anticancer drug Cabometyx...